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Background: Trichinellosis is an important foodborne zoonosis that is distributed worldwide. Trichinella spiralis may
evade host complement-mediated attack by expressing complement inhibitory proteins, such as paramyosin (Pmy).
Previous studies have shown that Trichinella spiralis paramyosin (Ts-Pmy) is able to bind to the human complement
component C9 to inhibit the complement activation and protect the parasite from complement-mediated attack.
Further determination of the complement-binding domain on Ts-pmy will enable us to better understand the
Ts-Pmy’s biofunction in the immune evasion and provide feasible approach to develop epitope-based subunit
vaccine against trichinellosis.
Methods: The complement C9 binding region on Ts-Pmy was determined by expression of overlapped fragments
of Ts-Pmy and their binding activities to C9. The exact binding site was further narrowed-down to a 14-amino acid
peptide at C-terminus using synthesized peptides with different size of amino acid sequence. The C9
complement-binding of the 14-amino acid peptide and its interference in the C9 polymerization and the
complement-mediated lysis of rabbit erythrocytes was investigated.
Results: The protein interaction between human C9 and native Ts-Pmy was further confirmed by
immunoprecipitation with T. spiralis lysates. The fragmental expression and C9 binding assays identified that the
binding region of Ts-Pmy to C9 is located within 831–885 of Ts-Pmy C-terminus. The exact binding site on Ts-Pmy to
C9 was narrowed down to 14 amino acid residues (866Val-879Met) by using different sizes of synthesized peptides. In the
presence of the synthesized 14-amino acid peptide, human C9 polymerization and the hemolytic activity of the human
complement was inhibited.
Conclusions: Our results revealed the precise molecular basis for T. spiralis to produce Ts-Pmy as an immunomodulator to
evade the attack of the host complement system as a survival mechanism.
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Trichinellosis is a globally widespread foodborne zoo-
nosis that occurs by ingesting raw or undercooked meat
of infected animals that contain parasitic larvae [1].
Muscle larvae (ML) are released from muscle tissue by
digestive enzymes in the stomach and migrate to the
small intestine, where the larvae develop into adult
worms (AD). Adult females produce newborn larvae
(NBL), which then penetrate into the mesenteric lymph-
atic vessels or the bloodstream and spread throughout
the body. Migrating NBL leave the capillaries and finally* Correspondence: zhuxping@ccmu.edu.cn
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unless otherwise stated.invade into muscle tissue, where the NBL develop to ML
and encapsulate in individual skeletal muscle cells [2].
Trichinella spiralis is the most common species that
infects human and mammalian hosts, such as pigs [3].
Human trichinellosis is characterized by high fever, facial
edema and myositis, which could be serious, particularly
in elderly patients [4]. Being regarded as an emerging or
re-emerging disease in some parts of the world due to
changes in diet and cooking practices [3,5], trichinellosis
is not only a public health hazard but also an economic
problem for livestock production and food safety [6,7].
Consequently, there is an urgent requirement for devel-
oping therapeutic and preventive vaccines to control the
infection [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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innate defense against infection and provides a vital first
line of defense against invading pathogens [9]. Among the
complement-evasion strategies to escape the host immune
attack, the capture of host complement components on the
parasite surface and then inactivating their functions is an
evasion mechanism that is frequently adopted by many par-
asites during the establishment of parasitism [10]. Similar
to other parasitic helminthes, T. spiralis utilizes molecules
or structures on the outermost cuticle/epicuticle to
bind complement components, such as C1q, C3, C5,
C8 and C9 [11-13], to evade the complement attach-
ment by inhibiting the formation of the membrane at-
tack complex (MAC) [13].
Paramyosin is a dimeric fibrillar protein that forms the
thick myofilaments of invertebrate muscle. In our previous
study, a full-length cDNA encoding T. spiralis paramyosin
(Ts-Pmy) was cloned by immunoscreening an adult worm
cDNA library using T. spiralis-infected rabbit sera [14].
BALB/c mice vaccinated with recombinant Ts-Pmy (rTs-
Pmy) developed a Th1/2 mixed immune response and were
partially protected against a T. spiralis larval challenge
[14,15]. Subsequently, the expression of Ts-Pmy was ob-
served on the outer membrane of newborn larvae and
adult worms using immunogold electron microscopy and
immunofluorescence staining [16]. A functional analysis
identified that rTs-Pmy was able to bind to the human
complement components C8 and C9, which consequently
inhibits the formation of MAC and thereby protects the
parasite from being attacked by activated complement [16].
However, the complement binding site on Ts-Pmy has not
been determined. In the present study, we expressed differ-
ent fragments of Ts-Pmy, characterized the interaction be-
tween different fragments of Ts-Pmy and the complement
component C9 and finally pinpointed the complement
binding site on Ts-Pmy within the region from 866Val
to 879Met at the C-terminus.
Methods
Ethics statement
Experimental animals were purchased from the Laboratory
Animal Services Center of Capital Medical University
(Beijing, China). Experimental procedures were reviewed
and approved by the Capital Medical University Animal
Care and Use Committee and were consistent with the
NIH Guide for the Care and Use of Laboratory Animals.
Parasites and antigen preparation
T. spiralis of ISS 533 strain was maintained in female
ICR mice and T. spiralis ML were recovered from the
muscles of infected mice by a standard pepsin/hydro-
chloric acid digestion method [17]. Adult worms were
collected from the intestines of an infected Wistar rat.
Crude somatic extracts of adult worms were prepared byhomogenizing the worms in 1× PBS, pH 7.4 and centrifu-
ging at 16,000 × g. The protein concentration of the ex-
tracts was determined by BCA assay kit (Merck, Germany).Immunoprecipitation
To further verify the protein interaction between the
human complement C9 and the native Ts-Pmy, immu-
noprecipitation was performed with T. spiralis adult ex-
tracts as described previously [18]. Protein G MicroBeads
(Miltenyi Biotec, Germany) were pre-incubated with 3 μg
of human C9 (Merck, Germany) and 2 μg of anti-C9 mAb
(IgG1, Abnova, Taiwan) for 30 min on ice. In total, 40 μg of
T. spiralis adult extracts was then added and incubated
overnight at 4°C with rotation. Beads were washed four
times with washing buffers (1% NP40, 50 mM Tris buffer,
pH 8.0) before being added with pre-heated 1× SDS gel
loading buffer to elute proteins. Samples were separated by
SDS-PAGE and probed with anti-Ts-Pmy mAb (7E2) [19].
IRDye 800CW-labeled goat anti-mouse IgG (LI-COR,
Germany) was used as the secondary antibody.Fragmental expressions of Ts-Pmy in E. coli
To identify and locate the binding site of Ts-Pmy that binds
to the human complement C9, the DNA encoding the N-
terminus (Ts-Pmy1-315), C-terminus (Ts-Pmy571-885) and
middle region (Ts-Pmy286-600) of T. spiralis paramyosin
with 30 amino acids overlapped were cloned into the bac-
terial expression vector pET28a, with 6-histidine expressed
at the N-terminus as tags (Merck, Germany). To further
locate the binding site at the C-terminus of Ts-Pmy, the
DNA encoding the fragments of Ts-Pmy571-695, Ts-
Pmy666-790, Ts-Pmy761-885, Ts-Pmy761-815, Ts-Pmy796-
850 and Ts-Pmy831-885 were subcloned into pET28a to
express the fragments of Ts-Pmy C-terminus. The recom-
binant plasmids with sequencing confirmed right reading
frames were transformed into competent E. coli BL21
pLysS cells, and the recombinant Ts-Pmy fragments were
induced with 1 mM IPTG at 37°C for 6 h. The expressed
fragments were purified from the induced bacterial lysates
using Ni-charged His-Bind columns (Merck, Germany).
The purified fragments were examined by Western blot
with a monoclonal anti-HisTag antibody (0.2 μg/ml; Merck,
Germany).Peptide synthesis
To finally determine the amino acid sequence that
binds to C9, the peptides with different amino acid
sequences within the C9 binding region (831Leu to
885Tyr) were synthesized by solid-phase peptide syn-
thesis (Aviva Bio, China). The obtained peptides were
purified up to 95% by preparative RP-HPLC and veri-
fied by mass spectrometry.
Figure 1 Binding of native Ts-Pmy to human C9 was identified
using immunoprecipitation. The extracts of T. spiralis adult worms
were incubated with human C9 and anti-C9 mAb and precipitated
with protein G beads. The binding complex was separated by 12%
SDS-PAGE and probed with anti-Ts-Pmy mAb 7E2. M, standard
protein marker; Lane 1, T. spiralis adult worm extracts only; Lane 2,
worm extracts incubated with anti-C9 mAb only as a control; Lane 3,
worm extracts incubated with human C9 and anti-C9 mAb.
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peptides to human C9
To determine whether the expressed recombinant Ts-
Pmy fragments bind to human C9, the fragments and
non-relevant control BSA (Sigma, USA) (2 μg each)
were subjected to SDS-PAGE under reducing conditions
and then transferred to a nitrocellulose membrane. After
blocking with 5% milk in PBS, the membrane was incu-
bated with human C9 (Merck, Germany) (1 μg/ml) at 37°C
for 2 h and then probed with anti-C9 mAb (0.2 μg/ml;
Abnova, Taiwan) at room temperature for 1 h. IRDye
800CW-labeled goat anti-mouse IgG (50 ng/ml; LI-COR,
Germany) was used as the secondary antibody.
To determine whether synthesized peptides bind to
human C9, the peptides and non-relevant control BSA
(Sigma-Aldrich, USA) (5 μg in 2.5 μl each) were spotted
onto a nitrocellulose membrane using a narrow-mouth
pipette tip. After blocking with 1% BSA in PBS, the
membrane was incubated with human C9 (1 μg/ml) at
37°C for 2 h and then with anti-C9 mAb (0.2 μg/ml) at
room temperature for 1 h.
All membranes mentioned above were detected and im-
aged using an Odyssey infrared imaging system (LI-COR,
Germany).
C9 polymerization assays
To determine the effect of the synthesized peptide on
C9 polymerization, human C9 (3 μg) was pre-incubated
with the synthesized peptide at 37°C for 40 min and
then incubated with 50 mM ZnCl2 in 20 mM Tris buffer
(pH 7.2) at 37°C for 2 h [20]. Zn2+-induced polymerized
C9 (polyC9) is resistant to dissociation by boiling in 1%
SDS and, thus, could be detected by SDS–PAGE [21].
The inhibition of C9 polymerization was shown by SDS-
PAGE on a 3 to 20% acrylamide gradient gel under
reducing conditions and stained with Coomassie blue.
The full-length rTs-Pmy was added as a positive control.
Recombinant Ts87 (rTs87), a specific T. spiralis secreted
protein [22], was used as a non-relevant control.
Hemolytic assay of the alternative complement pathway
The complement-mediated lysis of rabbit erythrocytes
(ER) was performed via the alternative pathway of com-
plement activation [12]. To identify whether the synthe-
sized peptide acts as an inhibitor or a neutralizer of the
complement-mediated lysis activated by the alternative
pathway, 100 μl of fresh normal human serum (NHS)
was pre-incubated with various amounts of synthesized
peptide or rTs-Pmy in Mg-EGTA solution (5 mM MgCl2,
10 mM EGTA) for 30 min before being added into freshly
prepared ER (1 × 10
8) in 100 μl HBSS (Hank’s Balanced Salt
Solution, without calcium and magnesium, pH 7.4, Gibco,
USA) at 37°C for 30 min. Heat-inactivated NHS was used
as a control. The hemolytic assay was stopped by adding1 ml of cold HBSS that contained 10 mM EDTA. After cen-
trifugation at 3,000 × g and 4°C for 10 min, the amount of
hemoglobin released into the supernatant was measured at
412 nm. The percentage of lysis (relative to cells completely
lysed by water) was then calculated. rTs87 was used as a
non-relevant control.Statistical analysis
The data were expressed as the mean ± standard error
(S.E.) and were evaluated using the software Prism 6
(GraphPad Inc., USA) with a one-way ANOVA; P <0.05
was regarded as statistically significant.Results
Binding of native Ts-Pmy to human C9
The protein interaction between human C9 and native
Ts-Pmy was further confirmed by immunoprecipitation
and Western blot analysis. Ts-Pmy in the adult worm ex-
tracts was specifically recognized by anti-Ts-Pmy mAb
7E2 (~102 kDa) (Figure 1, Lane 1). The native Ts-Pmy in
the adult extracts was bound to human C9, and the
binding complex was pulled down by anti-C9 mAb
(Figure 1, Lane 3). Anti-C9 mAb alone did not bind to
the native Ts-Pmy in the extracts (Figure 1, Lane 2). As
shown in lanes 2 and 3, the heavy chain and light chain
of anti-C9 mAb were pulled down by Protein G and rec-
ognized by the anti-mouse IgG secondary antibody.
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site to human C9
To identify the binding site of Ts-Pmy to human C9,
different fragments covering the whole molecule with 30
amino acids overlapped were expressed as recombinant
fragmental proteins (Figure 2A). The recombinant frag-
ments were transferred to a nitrocellulose membrane,
probed with human C9 and detected using anti-C9
mAb. The Western blot analysis demonstrated that the
binding site in Ts-Pmy to human C9 was located at the
C-terminus of Ts-Pmy (Ts-Pmy571-885) (Figure 2B).
Further fragment expressions were performed within
the C-terminus and the binding site was narrowed
down to Ts-Pmy761-885 (Figure 2C). Further pin-
point of the C9 binding region was determined by
smaller fragment expression, which is located within
Ts-Pmy831-885 (Figure 2D). As a non-relevant control,
BSA did not bind to human C9. All recombinant pro-
tein fragments could be recognized by anti-HisTag
antibody.Figure 2 Diagram of rTs-Pmy fragments and mapping of the Ts-Pmy
human C9, each fragment (with starting and ending positions) was cloned
protein (2 μg) starting from large fragments (B) down to smaller fragments
HisTag mAb (upper) or bound to human C9 and probed with anti-C9 mAb
used as the secondary antibody. The same amount of BSA (2 μg) was loadDetermination of the C9 binding site in Ts-Pmy by
synthesized peptide mapping
To further pinpoint the C9 binding site within the C-
terminus of Ts-Pmy (Pmy831-885) defined by the frag-
ment expressions, the 12 overlapped peptides covering
this region were synthesized for their binding capacity to
human C9 (Figure 3). After being spotted onto a nitro-
cellulose membrane, the synthesized peptide was probed
with human C9 and detected with anti-C9 mAb. The Dot-
blot analysis demonstrated that P8 within Ts-Pmy866-880
was able to bind to human C9 (Figure 3). The exact C9
binding sequence was narrowed down to Ts-Pmy866-879
(P10) by removing one amino acid at position 880. The fur-
ther removal of one amino acid at the N-terminus (P11) or
at the C-terminus (P12) caused the loss of the binding to
human C9 (Figure 3), indicating that the sequence of the
C9 binding site in Ts-Pmy was precisely narrowed down to
14 amino acid residues between 866Val to 879Met that forms
the binding site structure to C9. As a non-relevant control,
BSA did not bind to human C9.binding site to human C9. To identify the binding site of Ts-Pmy to
and expressed as a recombinant protein (A). Each recombinant
(C and D) were subjected to SDS-PAGE and then probed with anti-
(lower). IRDye 800CW-labeled goat anti-mouse IgG (50 ng/ml) was
ed as a non-relevant control. M: standard protein marker.
Figure 3 Further mapping of the C9 binding site in overlapped synthesized peptides. Different overlapped peptides within the C9 binding
fragment of Ts-Pmy (Pmy831-885) were synthesized, and then spotted onto a nitrocellulose membrane by using a narrow-mouth pipette tip
(5 μg in 2.5 μl). After being blocked with 1% BSA in PBS, the membrane was incubated with human C9 (1 μg/ml) at 37°C for 2 h and then with
anti-C9 mAb (0.2 μg/ml) at room temperature for 1 h. IRDye 800CW-labeled goat anti-mouse IgG (50 ng/ml) was used as the secondary antibody.
The peptide size diagram is shown on the left and the Dot-blot with C9 is shown on the right.
Figure 4 Inhibition of Zn2+-induced C9 polymerization by the
synthesized peptide P10. To determine the effect of the
synthesized peptide P10 on C9 polymerization, human C9 (3 μg)
was pre-incubated with different amounts of peptide P10 (0 μg,
2.5 μg, 5 μg and 10 μg) at 37°C for 40 min and then incubated with
50 mM ZnCl2 in 20 mM Tris buffer (pH 7.2) at 37°C for 2 h. Blank C9
without adding Zn2+ was used as a negative control. The full-length
rTs-Pmy (10 μg) was used as positive control and Ts87 (10 μg)
was used as non-relevant control. M, standard protein marker. The
reaction mixtures were analyzed by SDS-PAGE.
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peptide P10
To determine whether binding peptide P10 (866Val to
879Met) inhibits the Zn2+-induced C9 polymerization as
full-length rTs-Pmy [16], C9 was mixed with different
amount of peptide P10 (2.5, 5, 10 μg) and then incu-
bated with 50 mM ZnCl2. As shown in Figure 4, peptide
P10 inhibited Zn2+-induced C9 polymerization in a
dose-dependent manner. The polymerization of 3 μg hu-
man C9 was completely inhibited by 10 μg peptide P10
(Figure 4) and similarly by the full-length rTs-Pmy.
rTs87 (10 μg) did not inhibit C9 polymerization as a
non-relevant control. Without Zn2+, the C9 did not form
the polymer (Figure 4).
Inhibition of complement-mediated hemolysis by the
binding site peptide P10
After incubation with different amounts of peptide P10 and
rTs-Pmy (0, 5, 10, 20 μg), complement-mediated ER lysis
with NHS via the alternative pathway was significantly
inhibited in a dose-dependent manner (Figure 5), which
suggested that peptide P10 bound to C9 and consequently
inhibited the complement-mediated hemolysis. As a
non-relevant control, rTs87 did not inhibit complement-
mediated hemolysis.
Discussion
The complement system has a critical role in the recogni-
tion, opsonization and elimination of pathogenic intruders.
Among bacteria, viruses, fungi and parasites, many species
have developed specific complement-evasion strategies to
escape the attack from host’s immune system. The most
common complement-evasion mechanism is to capture thesoluble host complement regulators or express their struc-
tural mimics on the microbial surface [10]. Similar to other
pathogens, helminths have a particularly wide and diverse
arsenal of complement-evasion proteins, many of which
have been characterized recently [10].
Figure 5 Inhibition of complement-mediated hemolysis by
peptide P10. NHS was pre-incubated with various amounts (0, 5,
10, 20 μg) of peptide P10 and rTs-Pmy in Mg-EGTA solution (5 mM
MgCl2, 10 mM EGTA) for 30 min before adding the mixture into
freshly washed ER (1 × 10
8) in 100 μl HBSS at 37°C for 30 min. rTs87
was used as a non-relevant control. The amount of hemoglobin
released into the supernatant was measured at 412 nm, and the
percent lysis was calculated compared to the complete lysis (water).
The results are shown as the means ± SE for three independent
experiments. *p < 0.05. **p < 0.01.
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brate muscle and forms medullary rods surrounded by a
cortical array of myosin rods [23]. In helminths, para-
myosin serves not only as a structural protein but also
as an immunomodulator. Earlier studies identified the
expression of paramyosin in the tegument and on the
surface of Taenia solium [24], Schistosoma mansoni,
Schistosoma japonicum [25] and Fasciola hepatica [26].
It was observed that the paramyosin of helminth para-
sites could bind to human collagen [27-29], calgranulin
[30], IgG [25,28,29], IgA [31], C1q [32], C8 [33] and C9
[29,33], suggesting that surface-exposed paramyosin may
play an important role as a potential modulator of the
host immune system.
Our previous results showed that Ts-Pmy is present
on the outer membrane of the cuticle of the adults and
NBL of T. spiralis [16]. It was confirmed that surface-
exposed Ts-Pmy bound to complement C8 and C9,
which are important components of the complement ac-
tivation cascade and the membrane attack complex
(MAC). The polymerization of C9, which was induced
by Zn2+, was highly inhibited by rTs-Pmy, indicating its
interference in the assembly of the MAC during comple-
ment activation. The alternative complement pathway
that activates the complement complex or polyC9 on
rabbit erythrocytes (ER) was also inhibited by rTs-Pmy.
Native Ts-Pmy on the surface of T. spiralis effectively
protected NBL from attack by the host complement sys-
tem [14]. These results suggest that the outer membraneform of paramyosin expressed by T. spiralis had a role
in host immunomodulation, presumably by inhibiting the
formation of the MAC and thereby protecting the parasite
from being attacked by the activated complement.
In this study, we further confirmed that native Ts-Pmy in
the adult worm extracts was able to bind to human C9. In
order to determine the C9 binding site on Ts-Pmy, different
overlapped rTs-Pmy fragments were expressed as recom-
binant proteins and their ability to bind to C9 was tested.
The results showed that the C9 binding region was
located at the C-terminus of Ts-Pmy within position of
571–885, further narrowed down to the region be-
tween 831Leu and 885Tyr. To further map the complement
C9 binding site within Ts-Pmy831-885, we prepared ten
synthesized peptides covering the sequence of Ts-Pmy831-
885 with a few amino acids overlapping each other (P1-
P12). The result of the binding assay demonstrated that
15-amino acid peptides P8 (866–880) strongly bound to
human C9. Chopping off one amino acid at C-terminus
(P10) kept the same binding ability to C9, indicating that
the C9 binding site on Ts-Pmy consists of 14 amino acid
residues (866Val-879Met). Chopping off either 866Val (P12)
or 879Met (P11) lost the binding ability to C9, suggesting
that both residues at both ends of the binding site, 866Val
and 879Met, are necessary for the binding affinity to human
C9. A similar mapping study for the C9 binding site on
paramyosin of Schistosoma mansoni (Sm-Pmy) only nar-
rowed down to 123 amino acid residues in the C-terminus
[34]. Up to date, it is the first report to precisely locate the
C9 binding site of paramyosin in helminths.
Functional analysis in this study revealed that peptide
P10 (866Val-879Met) was comparable to bind to C9 and
further inhibit its function as full-length rTs-Pmy includ-
ing C9 polymerization and complement-mediated ER
lysis, suggesting that the binding site peptide could
effectively inhibit the assembly of MAC and therefore
protect the parasite from being attacked. Such results
were consistent with the observations in the study
on Sm-Pmy, which showed that C9 polymerization and
hemolytic activity of human complement was inhibited
by the C-terminal region of Sm-Pmy [34]. Therefore, the
C-terminal regions of Ts-Pmy and Sm-Pmy have similar
functions as complement inhibitors in capturing the
complement component C9 to evade the first line of
host’s immune defense as a survival strategy. T. spiralis pro-
duces Ts-Pmy through a 14 amino acids binding site to
bind and neutralize C9 as a direct complement inhibitor.
rTs-Pmy has been evaluated as a potential vaccine can-
didate antigen due to its complement neutralizing func-
tion [13,14]. The finding of the C9 binding domain on
Ts-Pmy provides a good therapeutic target and a feasible
approach to develop an epitope-based subunit vaccine
against trichinellosis. A monoclonal antibody against the
C9 binding domain has been produced and primary data
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passively transferred mice against T. spiralis larval infection
(data not shown), indicating its potential as an epitope
vaccine.
Our previous study revealed that another two epitopes
on Ts-Pmy recognized by protective monoclonal antibodies,
one of which is located between 88Glu and 107Glu at the
N-terminus of Ts-Pmy and another is a conformational
epitope without a specific location, were also protective in
immunized mice against T. spiralis larval challenge [19], in-
dicating Ts-Pmy may play multiple functions in the parasite
life cycle, except for acting as an immunomodulator
through neutralizing complement. A multi-epitope vaccine
based on these two Ts-Pmy epitopes and another protective
epitope from Ts87 produced higher levels of protection
compared to the individual epitope vaccine [16]. However,
the protection induced by these epitopes is not complete
(~35%). The addition of the C9 binding epitope identified
in this study into the multiple epitope pipelines may in-
crease the efficacy of protection against T. spiralis infection.
The protective immunity of the Ts-Pmy C9 binding domain
and its combination with other identified epitopes from
T. spiralis vaccine pipelines against T. spiralis infection is
under investigation.
Conclusions
This study mapped the C9 binding domain at the C-
terminus between 866Val and 879Met of vaccine antigen
Ts-Pmy, which was capable of binding to C9 and pre-
venting C9 polymerization. Our results revealed the pre-
cise molecular basis for T. spiralis utilizing Ts-Pmy as
an immunomodulator to resist the attack of the host
complement system. These results provide molecular
evidence that T. spiralis evades host complement attacks
by capturing and neutralizing complement components.
This functional understanding of complement-evasion
could serve as an important starting point for the devel-
opment of site-targeting therapeutics and epitope-based
subunit vaccines.
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